Jump to content

Lys-MDA

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Mfernflower (talk | contribs) at 06:42, 14 April 2024. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Lys-MDA
Clinical data
ATC code
  • none
Identifiers
  • (2S)-2,6-diamino-N-[1-(1,3-benzodioxol-5-yl)propan-2-yl]hexanamide
CAS Number
Chemical and physical data
FormulaC16H25N3O3
Molar mass307.394 g·mol−1
3D model (JSmol)
  • CC(Cc2ccc1OCOc1c2)NC(=O)C(N)CCCCN

Lys-MDA (Lysine-MDA, N-(L-lysinamidyl)-3,4-methylenedioxyamphetamine) is a substituted amphetamine derivative with empathogenic effects, which acts as a prodrug for MDA with a slower onset of effects and longer duration of action. Lys-MDA, along with the related derivative Lys-MDMA, are in early stage human clinical trials as potential treatments for treatment-resistant depression and post-traumatic stress disorder. New MDMA prodrugs are in the development phase at MiHKAL GmbH in Switzerland.[1][2][3][4]

Lys-MDMA [1]

See also

References

  1. ^ Buntz B (21 September 2022). "MindMed announces Phase 1 study of MDMA-like substances". Drug Discovery and Development.
  2. ^ "MindMed Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances". Biospace.com. 20 September 2022.
  3. ^ WO 2022/053696, Grill M, "Novel Safrylamine derivatives having prodrug properties.", published 17 March 2022, assigned to Compass Pathfinder Limited. 
  4. ^ WO 2023/283373, Clark S, Duncton MA, "Methylenedioxymethamphetamine and Related Psychedelics and Uses Thereof", published 12 January 2023, assigned to Terran Biosciences Inc.